FDA grants orphan drug designation to HLX22 for gastric cancer, with a phase 2 trial showing improved progression-free ...

two rare diseases. Currently, there are no approved therapies for treating wAIHA and IgG4-RD. Both diseases have a significant unmet medical need. The FDA grants orphan drug designation to support ...

Sanofi's reversible BTK inhibitor rilzabrutinib has gained the US Food and Drug Administration’s (FDA) orphan drug ...

There is still a significant unmet medical need for these two rare diseases, and neither have any currently approved medicine. FDA grants orphan drug designation to investigational therapies ...

IgG4-RD affects approximatively eight out of 100,000 adult patients in the US each year and is a rare, progressive, relapsing, chronic fibro-inflammatory condition which can manifest in almost every ...

Rilzabrutinib granted orphan drug designation in the US for two rare diseases with no approved medicines Designation granted for warm autoimmune hemolytic anemia and IgG4-related disease ...

“The Gaza Strip is suffering from the largest orphan crisis in modern history ... lasting for just about two months, Israeli forces kept the border crossings largely shut, turning away ...

Alberta Premier Danielle Smith says plans for cleaning up abandoned or inactive oil wells are to be made public in two weeks.

Sanofi SNY announced that the FDA has granted orphan drug designation to its investigational BTK inhibitor, rilzabrutinib, ...